REC 0/0559 Eye Drops for Treatment of Moderate & Severe Neurotrophic

Updated 05/10/2024

Status Recruiting

Clinical Trial Summary

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04276558
Study type	Interventional
Source	Recordati Rare Diseases
Contact	Béatrice Martin, PhD
Phone	+33147736458
Email	martin.be@recordati.com
Status	Recruiting
Phase	Phase 2
Start date	October 13, 2020
Completion date	May 2024

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04485546` - Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis	Phase 4
	Not yet recruiting	`NCT05927428` - Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis	Phase 2
	Completed	`NCT04552730` - Nerve Growth Factor for the Treatment of Cornea Disease
	Recruiting	`NCT04573647` - OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
	Completed	`NCT04820010` - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
	Recruiting	`NCT04627571` - Corneal Nerves After Treatment With Cenegermin
	Enrolling by invitation	`NCT05758753` - QST for Corneal Nerve Function	N/A
	Terminated	`NCT05809245` - Corneal Neurotization as a Treatment for Neurotrophic Keratopathy	N/A
	Withdrawn	`NCT05321251` - Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.	Phase 2/Phase 3
	Terminated	`NCT03037450` - Miniinvasive Corneal Neurotization. A Pilot Study.	N/A
	Not yet recruiting	`NCT06364657` - Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
	Recruiting	`NCT05566717` - An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
	Not yet recruiting	`NCT02707120` - Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis	Phase 4
	Completed	`NCT01756456` - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.	Phase 1/Phase 2
	Completed	`NCT02227147` - Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK	Phase 2
	Recruiting	`NCT05552261` - DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
	Recruiting	`NCT04909450` - Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects	Phase 1/Phase 2